Marshall Wace
ELDN icon

Marshall Wace’s Eledon Pharmaceuticals ELDN Stock Holding History

Marshall Wace’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,547
Closed -$44.6K – 3324
2025
Q4 		$44.6K Buy
+29,547
New +$70.2K ﹤0.01% 2784
2025
Q3 		– Sell
-94,772
Closed -$257K – 2995
2025
Q2 		$257K Buy
94,772
+75,572
+394% +$227K ﹤0.01% 2376
2025
Q1 		$65.1K Sell
19,200
-61,231
-76% -$252K ﹤0.01% 2523
2024
Q4 		$331K Buy
+80,431
New +$317K ﹤0.01% 2203

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Marshall Wace's ELDN Position: Q1 2026 in Review

Marshall Wace sold out of Eledon Pharmaceuticals (ELDN) in Q1 2026, closing a stake of 29,547 shares — an estimated $44.6K sold.

Marshall Wace first reported a position in ELDN in Q4 2024 and held it in 4 quarters. The position peaked at $331K in Q4 2024. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Marshall Wace reported no remaining Eledon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 29,547 Eledon Pharmaceuticals shares in Q1 2026, an estimated $44.6K.
  • Marshall Wace first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Marshall Wace's Eledon Pharmaceuticals position peaked at $331K in Q4 2024.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.